Gene therapy of pancreatic cancer with green fluorescent protein and tumor necrosis factor-related apoptosis-inducing ligand fusion gene expression driven by a human telomerase reverse transcriptase promoter

Annals of Surgical Oncology

Volumn 10, Issue 7, 2003, Pages 762-772

  Katz, Matthew H ^a   Spivack, Daniel E ^a   Takimoto, Shinako ^a   Fang, Bingliang ^c   Burton, Douglas W ^b   Moossa, A R ^a   Hoffman, Robert M ^a,d   Bouvet, Michael ^a,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d ANTICANCER INC   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Gene therapy; GFP; Pancreatic cancer; RFP; TRAIL

Indexed keywords

CASPASE; GREEN FLUORESCENT PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; APOPTOSIS REGULATORY PROTEIN; CASP3 PROTEIN, HUMAN; CASP3 PROTEIN, MOUSE; CASPASE 3; DNA BINDING PROTEIN; MEMBRANE PROTEIN; PHOTOPROTEIN; RED FLUORESCENT PROTEIN; TELOMERASE; TNFSF10 PROTEIN, HUMAN; TNFSF10 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENE FUSION; GENE IDENTIFICATION; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LIGAND BINDING; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PROMOTER REGION; PROTEIN EXPRESSION; ADENOVIRUS; ANIMAL; CELL CULTURE; DISEASE CARRIER; ENZYME ACTIVE SITE; METABOLISM; PANCREAS TUMOR; SUICIDE TRANSGENE; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; CARCINOMA, PANCREATIC DUCTAL; CASPASE 3; CASPASES; CATALYTIC DOMAIN; DNA-BINDING PROTEINS; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GREEN FLUORESCENT PROTEINS; HUMANS; INSECT VECTORS; LUMINESCENT PROTEINS; MEMBRANE GLYCOPROTEINS; MICE; PANCREATIC NEOPLASMS; TELOMERASE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0348054562     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/ASO.2003.01.021     Document Type: Article

References (31)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
2. Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999;189:1-7.
3. Bouvet M, Gamagami RA, Gilpin EA, et al. Factors influencing survival after resection for periampullary neoplasms. Am J Surg 2000;180:13-17.
4. Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 1997;226:248-57; discussion 257-60.
5. Breslin TM, Hess KR, Harbison DB, et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 2001;8:123-32.
6. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-82.
7. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996;271:12687-90.
8. Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997;276:111-3.
9. French LE, Tschopp J. The TRAIL to selective tumor death. Nat Med 1999;5:146-7.
10. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis- inducing ligand in vivo. Nat Med 1999;5:157-63.
11. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-62.
12. Kagawa S, He C, Gu J, et al. Antitumor activity and bystander effects of the tumor necrosis factor- related apoptosis-inducing ligand (TRAIL) gene. Cancer Res 2001;61:3330-8.
13. Ibrahim SM, Ringel J, Schmidt C, et al. Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death. Pancreas 2001;23:72-9.
14. Nitsch R, Bechmann I, Deisz RA, et al. Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet 2000;356:827-8.
15. Jo M, Kim TH, Seol DW, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000;6:564-7.
16. Gu J, Kagawa S, Takakura M, et al. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res 2000;60:5359-64.
17. Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998;279:349-52.
18. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-5.
19. Fang B, Ji L, Bouvet M, Roth JA. Evaluation of GAL4/TATA in vivo. Induction of transgene expression by adenovirally mediated gene codelivery. J Biol Chem 1998;273:4972-5.
20. Lin T, Gu J, Zhang L, et al. Targeted expression of green fluorescent protein/tumor necrosis factor- related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes. Cancer Res 2002;62:3620-5.
21. Bouvet M, Bold RJ, Lee J, et al. Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer. Ann Surg Oncol 1998;5:681-8.
22. Ghaneh P, Greenhalf W, Humphreys M, et al. Adenovirus-mediated transfer of p53 and p16(INK4a) results in pancreatic cancer regression in vitro and in vivo. Gene Ther 2001;8:199-208.
23. Bloomston M, Shafii A, Zervos EE, Rosemurgy AS. TIMP-1 overexpression in pancreatic cancer attenuates tumor growth, decreases implantation and metastasis, and inhibits angiogenesis. J Surg Res 2002;102:39-44.
24. Pirocanac EC, Nassirpour R, Yang M, et al. Bax-induction gene therapy of pancreatic cancer. J Surg Res 2002;106:346-51.
25. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998;281:1305-8.
26. Roth W, Reed JC. Apoptosis and cancer: when BAX is TRAILing away. Nat Med 2002;8:216-8.
27. Matsuzaki H, Schmied BM, Ulrich A, et al. Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells. Clin Cancer Res 2001;7:407-14.
28. Lin T, Huang X, Gu J, et al. Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. Oncogene 2002;21:8020-8.
29. Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A, Shimosegawa T. Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. Pancreas 2001;23:251-8.
30. LeBlanc H, Lawrence D, Varfolomeev E, et al. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 2002;8:274-81.
31. Xu ZW, Friess H, Buchler MW, Solioz M. Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis induced by chemotherapeutic agents. Cancer Chemother Pharmacol 2002;49:504-10.